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license (http://creativeimprovement merely due to previous exposure. The magnitude of such practice effects (PEs) may
be used as a marker of subtle cognitive impairment because they are diminished in healthy individuals
subsequently developing Alzheimer’s disease (AD).
Methods: To explore the relationship between sociodemographic factors, AD family history (FH),
and APOE ε4 status, and the magnitude of PE, four subtests of the Wechsler Adult Intelligence
Scale-IV were administered twice to 400 middle-aged healthy individuals, most of them first-
degree descendants of AD patients.
Results: PEs were observed in all measures. Sociodemographic variables did not show a uniform ef-
fect on PE. Baseline score was the strongest predictor of change, being inversely related to PEmagni-
tude. Significant effects of the interaction term APOE ε4*Age in processing speed and working
memory were observed.
Discussion: PEs exert a relevant effect in cognitive outcomes at retest and, accordingly, they must be
taken into consideration in clinical trials. The magnitude of PE in processing speed and working
memory could be of special interest for the development of cognitive markers of preclinical AD.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Preclinical; Cognition; Practice effects; APOE; Family history1. Introduction
Learning from previous experience is at the core of cogni-
tive ability in humans because it provides clear advantages
for adaptation [1]. When individuals are repeatedly exposed
to a problem or a task, they are expected to improve their per-
formance since they may have developed strategies and
memories that help them solve it better and/or in a more effi-
cient way. Tasks offered to an examinee during a neuropsy-
chological assessment are not free of these learning effects,
which may influence the interpretation of cognitive change.uthor. Tel.: 134-93-316-0990; Fax: +34-93-316-
anchezb@fpmaragall.org
16/j.dadm.2016.07.001
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).Even when subject’s ability, mood and motivation, and
exploration conditions remain stable, prior experience with
the tasks could still lead to improvements in performance.
These improvements that are merely due to previous experi-
ence are referred to as practice effects (PEs) [2]. Although
PE were classically viewed as a psychometric confound
that should be minimized or adjusted for, it has been more
recently suggested that they could represent a useful cogni-
tive variable. Reduced or absence of PE at short intervals
have been shown to enable the distinction of individuals
with and without cognitive impairment [3–5] and to
predict their long-term cognitive outcomes, as shown by
Duff and colleagues with an interval of one-week between
assessments [6–8]. Recent studies exploring PE at longer-
term intervals (e.g., annual assessments with severalimer’s Association. This is an open access article under the CC BY-NC-ND
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asymptomatic subjects that either progressed to mild cogni-
tive impairment (MCI) [9] or to symptomatic Alzheimer’s
disease (AD) [10]. As a whole, these reports suggest that
reduced PE may serve as a valuable indicator of preclinical
AD Stage III, since, in addition to positive AD biomarkers,
subtle cognitive changes would be present before meeting
criteria for a clinical diagnosis (i.e., MCI) [11]. Thus, the
study of PE is of special interest because they may be indic-
ative of subtle cognitive changes in persons performing
within “psychometrically normal” ranges (i.e., subjects
whose baseline and follow-up scores are per se not sugges-
tive of cognitive impairment).
Similar to most cognitive variables, the magnitude of PE
seems to be influenced by sociodemographic factors, such as
age and education. In a thorough meta-analysis, Calamia
et al. reported a consistent negative effect of age in PE
[12], although some studies have not observed such relation-
ship [13–15]. Although less studied, the level of formal
education has also shown disagreeing results. Although
some studies found a positive influence [16], other failed
to find such relationship [13,17]. Another key variable that
is frequently taken into account in PE studies is the length
of the time interval between assessments. As previously
mentioned, a wide range of intervals have been studied,
encompassing administrations within the same day (e.g.,
[3]), one-week retests (e.g., [18]), and sessions spared by a
year or more (e.g., [9]). The general evidence suggests that
shorter intervals are related to higher gains at retest, being
this improvement virtually zero after 5 years (see [12]),
although some reports have found evidence of PE after 7
or more years [19].
Other variables, such as gene pool, can likely influence the
magnitude of PE. Presence of the APOE ε4 allele of the
Apolipoprotein E (APOE) gene has been related to a small
but consistent decrease in cognitive performance in healthy
adults [20]. The APOE gene genotype is also known to influ-
ence the risk of developing late-onset AD, with subjects car-
rying one or two APOE ε4 alleles presenting a 3-fold and 12-
fold increased risk, respectively [21]. However, the effect of
APOE ε4 status only accounts for less than one third of the
estimated disease heritability [22] and other genetic and
nongenetic factors, such as environmental exposures, life-
style or nutrition, also modulate the risk of suffering AD.
The concept of family history of AD (FH) captures both ge-
netic and nongenetic factors in measuring AD risk (reviewed
in [23]). Some studies suggest that FH and APOE are inde-
pendent and additive risk factors for developing the disease
[24,25] and that both can be useful as markers to stratify
healthy subjects in different risk level groups [26].
Few studies have addressed the impact of carrying an
APOE ε4 allele and/or having FH of AD in the magnitude
of PE. Zehnder in 2009 and Donix in 2012 reported a nega-
tive association between the APOE ε4 allele and PE in mem-
ory tasks [27,28], but, more recently, Jonaitis et al. did not
find any relationship in a larger sample with an extendedcognitive test battery [26]. By contrast, in this latter per-
formed in the context of the Wisconsin Registry for Alz-
heimer’s Prevention (WRAP) study, Jonaitis et al. did find
a slight attenuation of PE related to the number of previous
visits in positive FH healthy middle-aged subjects.
In this scenario, in which the effect of subject character-
istics on PE remain unclear, and taking into account the
possible utility of such cognitive outcome as a marker of pre-
clinical AD, further knowledge on the possible moderator ef-
fect of individual variables in PE is necessary. In this study,
we aimed to provide further data on the topic by studying the
impact of age, sex, education, risk of AD related to FH of the
disease, and APOE ε4 status, on PE when re-testing 1 to 3
months from baseline.2. Methods
This study was carried out as part of a wider research plat-
form: the Alzheimer and Families (ALFA; Clinicaltrials.gov
Identifier: NCT01835717) parent cohort. Details of the study
along with an extended description of inclusion and exclu-
sion criteria are described elsewhere [29]. ALFA partici-
pants are cognitively healthy men and women aged
between 45 and 74 years, most of them first-degree descen-
dants of AD patients. Participants included in the parental
ALFA cohort during the first four months of recruitment
(April–July 2013) were consecutively offered the possibility
of attending a second visit 6 weeks (62) after and were
included in the present study.
The study was approved by the Ethics Committee of the
“Parc de Salut Mar” (Barcelona, Spain) and conducted in
accordance to the directives of the Spanish Law 14/2007,
of 3rd of July, on Biomedical Research. All participants
signed an informed consent form and had a close relative,
who also granted their consent, volunteering to participate
in the functional assessment of the participant.2.1. Participants and procedure
In the context of a validation study of a memory task per-
formed within the ALFA parent cohort, 400 individuals aged
between 45 and 65 years from this cohort were administered
twice four subtest of the Wechsler Adult Intelligence Scale-
IV in two visits (Visit 1, V1; Visit 2, V2) separated by a time
interval of 6 weeks (62 weeks). These tests were adminis-
tered in the time between immediate and delayed recall at
both visits. To diminish possible rehearsal in the intervisit in-
terval, participants were not told that they would repeat in
V2 exactly the same tests as in V1. Mood state was recorded
by means the Goldberg Anxiety and Depression Scale
(GADS) at both visits.
Information about vascular risk factors was also
collected. The REGICOR cardiovascular risk function, an
adaptation of the Framingham function validated in a Span-
ish sample [30] that estimate participants’ risk of suffering
coronary disease events at 10 years was calculated. In
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CAIDE (Cardiovascular Risk Factors, Aging, and Demen-
tia) score [31] was estimated. We calculated both model I
and model II CAIDE scores, which differ in the inclusion
(model II) or not (model I) of the APOE status. The genotype
of nine individuals could not be determined.
FH of AD was considered positive when at least one of
the participant’s parents developed AD before 75 years
(FH1). If the participant does not have any parent with
AD or they developed AD after 74 years, they were classified
as negative (FH2). This 75-year cutoff was selected based
on the evidence from recent studies on age-dependent ge-
netic risk that propose that genetic load exerts a higher influ-
ence before this age (see [32,33]).2.2. Cognitive measures
Four WAIS-IV subtests were administered using the
Spanish version of the scale [34]. The administered subtests
were as follows: The digit span subtest (score range, 0–48)
measures short-term and working memory and is composed
of three parts: forward (score range, 0–16), backward (score
range, 0–16), and sequencing (score range, 0–16). The cod-
ing subtest (score range, 0–135) measures, among others,
processing speed, short-term visual memory, visual percep-
tion, coordination, and attention. The matrix reasoning sub-
test (score range, 0–26) measures fluid intelligence, visual
organization, ability to identify part-whole relationships,
and simultaneous processing. Finally, the visual puzzles sub-
test (score range, 0–26) assesses visuospatial and fluid intel-
ligence, spatial manipulation, and the anticipation of
relationships between parts. All tests were administered by
trained neuropsychologists following the instructions of
the published manual. More information about the tasks
can be consulted in the Supplementary Materials section
of the current manuscript and in the technical manual [34].2.3. Statistical analyses
Initial descriptive analyses were performed. Raw scores
with wider ranges instead of scaled scores were used because
they are more sensitive to change. Pearson correlations be-
tween V1 and V2 scores and Cohen’s d effect size indices
were computed. Simple discrepancy scores between visits
were calculated by subtracting V1 score from V2 score.
Higher discrepancy scores (i.e., positive) result from
improvement in V2, whereas lower ones (i.e., negative)
emerge from decline in performance at V2. V2/V1 ratios
were also computed. Paired t tests were used to assess
whether change between visits was significant.
As an initial approach to analyze the effect of individuals
risk forAD indiscrepancy scores groupmeanswere compared
depending on APOE ε4 status (group 0, no APOE ε4 alleles
and group 1, at least 1 APOE ε4 allele) and FH (0 for absent
and 1 for at least having one parent that developed AD before
75 years). Because discrepancy scores were approximatelynormal (absolute values of skewness and kurtosis,1, except
for Coding, which showed a slight leptokurtic distribution,
kurtosis 5 1.37), parametric tests were used. APOE ε4 and
FH groups were compared by means t tests for independent
samples. Subjects were also grouped depending on the num-
ber of APOE ε4 alleles (0, 1, 2), and discrepancy scores
were compared among groups using a one-way ANOVA and
post hoc tests (Tukey). The associations between raw discrep-
ancy scores and age, education, intervisit interval, and base-
line score were initially analyzed using simple regression
analyses. Univariate general linear models were constructed
to further explore the influence of variables related to AD
risk, namelyAPOE ε4 status and FH ofAD in the discrepancy
of scores between visits. In these models, APOE ε4 status and
FHwere entered as random factors and intervisit interval, age,
education, sex and baseline score vascular risk scores and
discrepancy in GADS as covariates. Simple discrepancy
scores in digit span total, coding, matrix reasoning, and visual
puzzles were considered as dependent variables. Main effects
and interactions of interest (i.e., APOE ε4*FH, APOE
ε4*Age, and FH*Age) were studied. Subsequent models
keeping covariates, main factors of interest (APOE ε4 status
and FH), and significant interactions under P 5 .01 were
finally fitted. Sequential type I sum of squares were used to
conform the principle of marginality, in which higher order
terms are entered after all corresponding lower order terms.
Modelswere constructedwith covariates first,APOE ε4 status
and FH (in this order) in second term and, finally, two-way
interaction terms. In final models, significant main effects
were only interpreted when no significant interaction
(P..05)was present.As previously stated,with the exception
of the selection step of relevant interactions (P. .01), signif-
icance threshold was set at P 5 .05. R statistical software
(v.3.2.0) was used to conduct the analyses and to plot graphs.3. Results
The study sample was composed of slightly more
women (60%) than men and included a noticeable per-
centage of APOE ε4 carriers (36.3%). The percentage of
carriers was higher in the FH1 group (39.6% vs.
31.7%), but this difference did not reach statistical signif-
icance (c2 [1,N 5 388] 5 2.25, P 5 .13). The mean years
of formal education were 14. Retest interval ranged from
15 to 78 days with a mean interval of 46 days
(SD 5 10.35). Only 2.5% of the individuals were retested
in ,4 weeks and 14.8% in .8 weeks. A more detailed
description of the sample, including scores in cognitive
screening tests and cardiovascular risk scores, is found
in Table 1. Table 2 shows these demographic and scale
characteristics of the study participants according to their
APOE and family history status.
Table 3 shows the raw scores at both visits and the
discrepancy indices. As a whole, the group showed statisti-
cally significant improvements at V2 in all WAIS-IV sub-
tests. The mean increase was of 6.5% (mean of the
Table 1
Sociodemographic, basic cognition, vascular-related risk scores, and
genetic description of the study sample
Mean SD
Age (y) 53.43 5.39
Education (y) 13.96 3.41
MMSE 29.06 1.06
MIS 7.79 0.52
Semantic fluency (animals) 23.28 5.22
Interval between visits (d) 46.00 10.35
REGICOR (n 5 359)* 3.68 1.97
CAIDE model I (n 5 360)y 2.33 3.08
CAIDE model II (n 5 353)z 2.34 3.66
Count/total Percentage
Females 240/400 60.0
At least one APOE ε4 allele 142/391 36.3
Presence of family history of AD 357/400 89.3
AD onset ,75 (FH1) 231/354 65.3
AD onset 75 123/354 34.7
No history of AD 43/400 10.7
No history of AD or AD onset 75 (FH2) 166/397 41.8
Abbreviations: MMSE, mini mental state examination; MIS, memory
impairment screen; REGICOR, Registre Gironı del Cor function; CAIDE,
Cardiovascular Risk Factors, Aging, and Dementia function; SD, standard
deviation.
*Risk of suffering coronary disease events at 10 years in percentage.
yModel I, probability in percentage, of dementia in 20 years without
APOE status.
zModel II, probability in percentage of dementia in 20 years with APOE
status.
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in each of the four main variables). Presence of anxiety
and depression symptoms in the sample, as assessed by the
GADS, showed minimum, nonsignificant, mean change be-
tween visits (V2-V1 GADS anxiety,M520.10, SD5 1.45,
t(399) 5 1.45, P 5 .149; V2-V1 GADS depression,
M 5 20.03, SD 5 0.68, t(399) 5 0.880, P 5 .380).Table 2
Sample characteristics according to APOE and family history status
APOE ε4
Carriers
N 142
Age, y, mean (SD) 52.84 (5.26)
Education, y, mean (SD) 14.01 (3.37)
% females 54.93
MMSE, mean (SD) 29.11 (1.07)
MIS, mean (SD) 7.80 (0.48)
Semantic fluency (animals), mean (SD) 24.15 (5.09)
Interval between visits (d), mean (SD) 45.76 (10.42)
REGICOR (n 5 359)y %, mean (SD) 3.75 (1.95)
CAIDE model I (n 5 360)z %, mean (SD) 2.44 (3.35)
CAIDE model II (n 5 353)x %, mean (SD) 3.42 (4.92)
Abbreviations: MMSE, mini mental state examination; MIS, memory impairme
cular risk factors, aging, and dementia function; SD, standard deviation.
*P , .05 in independent samples t test.
yRisk of suffering coronary disease events at 10 years.
zModel I, probability of dementia in 20 years without APOE status.
xModel II, probability of dementia in 20 years with APOE status.3.1. Means discrepancy and AD risk profile
No mean differences in the discrepancy indices in cogni-
tive scores (V2–V1) were observed between groups when in-
dividuals were classified based on their risk for AD profile,
neither between APOE ε4 carriers and noncarriers nor be-
tween individuals with and without FH.When coding partic-
ipants’ APOE status based on the number of APOE ε4 alleles
(0, 1 or 2), differences remained nonsignificant.3.2. Sociodemographic, baseline performance, and
intervisit interval effects on PE
Univariate simple linear regression analyses were applied
to explore the relationship between discrepancy scores and
age, education, intervisit interval, and baseline performance.
Fig. 1 shows the scatterplots and the results of simple univar-
iate regression analyses between discrepancy scores and age,
education, intervisit interval, and baseline score. In these
models, age did not predict any discrepancy score, whereas
education only significantly predicted the discrepancy in vi-
sual puzzles scores (the more the education the higher the
PE). Intervisit interval predicted discrepancy in coding and
matrix reasoning (in both cases, shorter intervals were
associated to higher PE). Baseline scores were the strongest
predictors of discrepancy scores, showing an inverse
relationship in all the cases.3.3. Effect of AD risk variables on PE
All APOE ε4 and FHmain effects resulted nonsignificant.
However, the interaction term APOE ε4*Age was found to
be statistically significant for the coding discrepancy score
(F(1,379) 5 5.20, b 5 20.304, P 5 .023, hp
2 5 0.014),
and quasi-significant for the digit span one
(F(1,379) 5 3.64, b 5 20.124, P 5 .057, hp
2 5 0.010). InFamily history of AD onset ,75
Noncarriers Positive Negative
249 231 166
53.84 (5.43) 52.59 (5.20) 54.62 (5.49)*
13.95 (3.42) 14.06 (3.30) 13.81 (3.57)
61.85 56.71 64.46
29.04 (1.04) 29.12 (0.98) 28.96 (1.15)
7.79 (0.51) 7.80 (0.51) 7.78 (0.50)
22.80 (5.22)* 23.10 (5.03) 23.52 (5.49)
46.31 (10.46) 46.74 (10.74) 45.10 (9.78)
3.64 (2.01) 3.52 (1.89) 3.88 (2.07)
2.30 (2.96) 2.16 (2.72) 2.59 (3.55)
1.72 (2.49)* 2.13 (2.90) 2.66 (4.56)
nt screen; REGICOR, Registre Gironı del Cor function; CAIDE, cardiovas-
Table 3
V1 and V2 scores, discrepancy indices, correlations, and effect sizes
V1 V2 V2-V1 Ratio V2/V1 r d
Digit span total 25.73 (5.35) 26.60 (5.35)* 0.87 (3.49) 1.046 (0.153) 0.788* 0.16
Digit span forward 8.79 (2.18) 9.01 (2.27)* 0.22 (1.95) 1.052 (0.248) 0.615* 0.10
Digit span backward 8.30 (2.16) 8.59 (2.17)* 0.29 (1.84) 1.064 (0.238) 0.639* 0.13
Digit span sequencing 8.65 (2.11) 9.01 (2.27)* 0.36 (1.95) 1.081 (0.358) 0.589* 0.16
Coding 69.86 (13.71) 74.27 (14.36)* 4.46 (6.81) 1.070 (0.112) 0.883* 0.31
Matrix reasoning 17.51 (4.18) 18.11 (4.14)* 0.60 (3.52) 1.066 (0.262) 0.643* 0.14
Visual puzzles 14.64 (4.23) 15.25 (4.21)* 0.61 (3.30) 1.078 (0.255) 0.694* 0.15
NOTE. Means and (standard deviations) are shown. *P , .05. Paired t tests were applied to test the difference in means between V1 and V2. r, Pearson
correlation. d, Cohen’s effect size. For digit span, variables direct scores are displayed.
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dicted matrix reasoning change (F(1,379) 5 5.28,
b5 0.134, P5 .022, hp
25 0.014). Simple slopes stratifying
by APOE ε4 status or FH as appropriate were calculated and
can be seen in Fig. 2. APOE ε4 carriers displayed a decline in
PE with advancing age, whereas noncarriers did not show
such pattern. With regard to FH, individuals categorized as
negative showed an attenuation of PE with advancing age,
whereas participants that had at least one of their parents
that had suffered AD before the age of 75 years did not
have such attenuation. To further explore the possible causes
of such unexpected pattern, means in baseline score, interval
between visits, age, and education were compared between
FH1 and FH2 groups. Significant mean differences were
found for age, being the FH1 group younger than the
FH2 (FH1 [M 5 52.6, SD 5 5.2], FH2 [M 5 54.6,
SD 5 5.5], t(395) 5 3.75, P , .001), and mean baseline
scores, being higher in the FH1 group (FH1 [M 5 18.0,
SD 5 3.8], FH2 [M 5 16.9, SD 5 4.6], t(395) 5 22.7,
P 5 .007). As previously stated, no statistically significant
differences between groups in the number of APOE ε4 car-
riers was found. Next, we also analyzed whether the same re-
sults were obtained when FH was introduced before APOE
ε4 status in the model. This did not produce relevant changes
in the output.
Finally, four additional models were constructed adding
interaction terms between scores at V1 and age, education,
APOE ε4 status, and FH. The V1*Age term on coding
discrepancy scores was the only significant interaction
(F(1,376) 5 6.75, b 5 20.012, P 5 .01, hp
2 5 .018).
Vascular risk scores (REGICOR and CAIDE I and II) did
not significantly predict discrepancy scores in any model,
but we found significant moderate negative Pearson correla-
tions between them and performance in Coding at V1 (RE-
GICOR r 5 20.25, CAIDE model I r 5 20.33, CAIDE
model II r 5 20.35) and low ones (r value around 20.10)
with digit span, matrix reasoning, and visual puzzles.4. Discussion
This study aimed at exploring the effects of sociodemo-
graphic variables, baseline performance, APOE ε4 status,
andFHofAD in themagnitudeofPE innonmemorymeasuresin a sample of cognitively normal middle-aged adults. Glob-
ally, a mean improvement of 6.5% in performance was
observed at V2. We calculated discrepancy scores (V2–V1)
and studied the effect of subjects’ characteristics. Age did
not predict PE in any variable, whereas education predicted
PE in visuospatial reasoning. Baseline score was in all cases
the strongest predictor of change showing an inverse relation-
ship to themagnitude of PE.AD risk factors, namelyAPOE ε4
and FH, did not show significantmain effects in PE. However,
we observed that APOE ε4 carriers displayed less improve-
ment at V2 in processing speed and working memory when
associated with increasing age. In addition, FH2 subjects
showed attenuated PE also associated with increasing age.
We have observed consistent PE for most variables. All of
them yielded significance in the paired t test for mean differ-
ences. The higher effect size between visits was found for
coding (d 5 .31) and the lower for digit span forward
(d 5 .10). These findings are in agreement with the sugges-
tion that timed tests that require an infrequently practiced
response, such as substitution tasks, tend to be more suscep-
tible to PE [35]. Although the comparison with previous re-
ports is not straightforward, because studies differ in
subjects’ characteristics, test-retest intervals, and types of
used tasks, the magnitude of the PE found in this study mir-
rors prior evidence, either using the same WAIS subtests
[34–36] or other comparable neuropsychological measures
[15,17].
Sociodemographic variables were overall poor predictors
of gains or losses at retest. Age did not significantly predict
any discrepancy score in univariate regressions, whereas ed-
ucation showed an effect only in visual puzzles discrepancy
score. This globally negative findings match those previous
studies that reported no relevant influences of age and edu-
cation on PE [13–15,37]. However, it is worth mention
that our results could be substantially driven by the narrow
age range and the homogeneous middle-upper education
of the studied sample.
Baseline performance exerts a strong effect in discrep-
ancy outcomes. Previous literature suggests that when it
comes to PE, the “richer get richer” rule applies [37], under
the assumption that high performers would take more advan-
tage from previous exposition to the task. In contrast, we
found that participants with lower baseline scores tend to
Fig. 1. Scatterplots and results of simple univariate regression between discrepancy scores and age, education, intervisit interval, and baseline scores. Signif-
icant coefficients: Education for visual puzzles discrepancy score [b5 0.134, t(398)5 2.79, P5 .006, R2 5 0.019]. Intervisit interval for coding discrepancy
score [b520.072, t(398)522.21,P5 .028,R25 0.012] andmatrix reasoning [b520.036, t(398)522.11,P5 .035,R25 0.011]. Baseline for discrepancy
scores in digit span [b 5 20.211, t(398) 5 26.84, P , .001, R2 5 0.105]; coding [b 5 20.074, t(398) 5 23.01, P , .001, R2 5 0.022]; matrix reasoning
[b 5 20.363, t(398) 5 29.54, P , .001, R2 5 0.186]; and visual puzzles [b 5 20.308, t(398) 5 28.57, P , .001, R2 5 0.156].
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some other reports [38]. One plausible explanation for this is
related to the “regression to the mean” phenomenon, in
which extreme values at baseline tend to lie closer to the
mean at retest. In addition, the special features of the studied
measures can also contribute to this effect. WAIS scales are
performance-based tests designed to obtain the maximum
performance of a given subject in a single application.Therefore, such maximum-performance approach would
minimize the capability of improvement at retest. In any
case, our results confirmed that PEs exert a nondismissible
influence in performance that should be accounted for and
consciously addressed for a proper interpretation of cogni-
tive outcomes. This issue is fundamental for clinical trials
in which, in addition to the use of a control group, additional
recommendations for controlling for PE have been
Fig. 2. Simple slopes showing the relationship between PE and age stratifying by APOE ε4 [(A) for the discrepancy score [V2 minus V1] in coding and (B) for
digit span] or by FH [(C) for the discrepancy matrix reasoning].
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studies. These include multiple prebaseline testing, the use
of reliable change indices and alternate forms, and
practice-insensitive tests [39].4.1. Risk factors for AD
No differences in PE were observed between AD risk
groups, neither when grouping by the presence or the absence
of the APOE ε4 allele, nor by having or not a relevant FH
antecedent as defined in our study. Our results partially
concur with Jonaitis et al. findings in the context of the
WRAP study [26]. They did not observe significant APOE
ε4 effects on PE but found an interaction effect between
FH and the number of previous assessments in the factors
speed and flexibility and working memory. Interestingly,
we observed significant effects on tasks tapping these same
domains for the interaction term between APOE ε4 and age
in PE (i.e., coding and digit span), with carriers showing
less improvement at V2 as they age. Despite obvious differ-
ences between both studies and results, the convergence of
domains in which diminished PE related to both risk factors
gives additional credit to the importance of studying PE in
tasks tapping processing speed and working memory for
the detection of initial signs of subtle cognitive decline.
In addition, our results also partially reproduce a counter-
intuitive pattern observed by Jonaitis et al. They found a sig-
nificant effect of the interaction between FH and age
consisting in a worse age-related change in speed and flexi-
bility in subjects without antecedents of AD [26]. We found
a similar pattern for the PE in matrix reasoning, in which
FH2 subjects displayed attenuated PE as they age. Jonaitis
et al. discussed their results in the context of controlling the
effect of age as a linear covariate and suggested that this ef-
fect might sometimes show a nonlinear (quadratic) behavior.
Should the effects of aging be nonlinear, accounting for this
factor with a linear term would not completely remove this
component, and as consequence, this may cause some unex-
pected behavior in the dependent variable. Another possible
explanation of such unexpected result could be a high degreeof collinearity between the FH and APOE covariates. In this
event, if the two variables are strongly correlated, it might be
impossible to dissociate their distinct impact on the depen-
dent variable. To evaluate these two alternatives, we further
explored the reliability of the interaction with two additional
statistical models. When age was entered as a quadratic fac-
tor, the direction of the interaction was reversed (FH1
showed less PEwhen age). On the other hand, the interaction
remained unchanged when we removed APOE status as a
factor, therefore discarding collinearity as a potential expla-
nation. These results suggest that the interaction effect be-
tween age and FH on cognition may arise from a nonlinear
effect of aging. Conversely, no changes in the direction of
the effects of the interaction term APOE ε4*Age were
observed. Taken together, these results highlight the impor-
tance of appropriately covariating the effect of aging on the
measurements of cognitive outcomes. Previous evidence
from neuroimaging studies has shown that healthy aging is
a nonlinear process and therefore is better modeled using a
quadratic approach (e.g., [40–43]). In addition, cognitive
aging has also shown to follow a quadratic pattern (e.g.,
[44]).
Our definition of FH that is dependent on parental age of
onset of AD could have also had an impact in our results.
Previous studies have limited the age of onset of the AD
antecedent to ,85 [45] or ,80 [46] because “dementia
occurring at a very old age is less likely to have a strong ge-
netic component” [45]. In our study, a cutoff of 75 years was
selected based on the evidence from recent studies on age-
dependent genetic risk that propose that genetic load exerts
a higher influence before this age (see [32,33]). In addition,
our recruitment strategy for the wider parent cohort (mainly
first-degree descendants of AD patients) may have also
introduced a potential bias in the present study.
Our results support the idea that working memory may
be a key domain in the detection of subtle cognitive decline
in preclinical AD. Recent studies have found a greater
decline only in the attention/working memory domain in
subjects without cognitive impairment that had evidence
of neuropathologic AD change [47]. In addition, working
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with parental history of AD, with APOE ε4 status explain-
ing not much of this heritability, and it is suggested to be a
cognitive target for future genetic studies [48]. Because PEs
are also suggested to be useful as a subtle cognitive marker
sensitive to preclinical AD, a more thorough evaluation of
PE in working memory could be of high interest. Within
this preclinical AD phase, characterized by pathophysio-
logical changes occurring decades before the emergence
of clinical symptoms, a late stage that encompasses “subtle
cognitive impairment” has been proposed (stage III) [11].
Although the concept of “subtle cognitive impairment” is
still not fully operationalized, some works that have
recently addressed the topic, have consistently proposed
the use of intra-subject measures, either by studying cogni-
tive decline during time or the magnitude of PE [10,26]. In
addition, the latter has been demonstrated to be an
inexpensive, useful tool to identify subjects for the
enrichment of clinical trial samples aiming at recruiting
amyloid-positive participants [49].
The main limitation of the present study is its transversal
nature. The longitudinal follow-up of participants, currently
underway, will allow us to assess for the ability of PE to pre-
dict cognitive decline. Furthermore, these studies will help
ascertain whether PE in the cognitive domains under study
here may be used as cognitive markers for preclinical AD.
In addition, in this study, we measured PE with four
WAIS-IV subtests, whereas episodic memory, which is the
domain that showed the most consistent PE, is not included
in the current analyses. A preliminary study in a much
smaller sample from the ALFA cohort in which we analyzed
PE on the memory binding test showed a 10% to 26% of
improvement in V2 [50]. Nevertheless, the study of practice
effects (PE) in nonmemory domains is still highly relevant in
subjects at risk of AD.Machulda et al. [9] found that subjects
that remained cognitively stable had PE in the memory, lan-
guage, attention, and visual reasoning domains at retest. In
contrast, subjects who declined (either to incident MCI or
dementia in the following 6 years) showed diminished PE
in the language, attention, and visual reasoning domains
but not in memory. Similarly, Wilson et al. [51] pointed
out that a change in semantic and working memory preceded
the decline in other domains.
The narrow age range of participants may also be seen a
priori as a limitation. Nonetheless, we found relevant AD
risk and age interaction effects in PE, and these results point
out to a possible strong interaction betweenAPOE ε4 and FH
status and age that will be confirmed in longitudinal studies.
Finally, as noted by Jonaitis et al. [26], although studies on
healthy middle-aged adults do not have the development
of MCI or dementia as endpoints, they are useful to seek
for antecedent cognitive phenotypes stratifying the samples
by known markers of dementia risk, such as APOE ε4 or FH
status.
In summary, our main result is that PEs are part-
ially affected by individual characteristics and baselineperformance in healthy middle-aged subjects. AD risk fac-
tors, namely APOE ε4 and FH, interactions with age show
an effect in the magnitude of PE in some tasks. In line
with previous reports, our results suggest that PE in the pro-
cessing speed and working memory domains could be of
special interest for the development of cognitive markers
of preclinical AD. Our data add evidence on the fact that
PEs exert a relevant effect in cognitive outcomes at retest,
and accordingly, they must be taken into consideration in
clinical trials for preclinical AD (for example using multiple
prebaseline testing or alternate forms of the same test).
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1. Systematic review: Previous reports on the relation-
ship of individuals’ characteristics on practice effects
(PE) are cited throughout the manuscript.
2. Interpretation: The relationship between sociodemo-
graphic factors, Alzheimer’s disease (AD) family
history and APOE ε4 status, and the magnitude of
PE in 400 participants (45–65 years), most of them
first-degree descendants of AD patients, was as-
sessed for four subtests of the WAIS-IV. PEs were
observed in all measures. Sociodemographic vari-
ables did not show a uniform effect. Baseline score
was the strongest predictor of change, being
inversely related to PEmagnitude. Significant effects
of the interaction term APOE ε4-age in processing
speed and working memory were observed.
3. Future directions: PEs must be considered in clinical
trials in preclinical AD (for example with multiple
prebaseline testing or by suing alternate forms). PE
in processing speed and working memory could be
of special interest for the development of cognitive
markers of preclinical AD.
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